Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Melanoma

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 32 articles:
HTML format



Single Articles


    May 2022
  1. PHELPS GB, Hagen HR, Amsterdam A, Lees JA, et al
    MITF deficiency accelerates GNAQ-driven uveal melanoma.
    Proc Natl Acad Sci U S A. 2022;119:e2107006119.
    PubMed     Abstract available


    March 2022
  2. KAVRAN AJ, Stuart SA, Hayashi KR, Basken JM, et al
    Intermittent treatment of BRAF(V600E) melanoma cells delays resistance by adaptive resensitization to drug rechallenge.
    Proc Natl Acad Sci U S A. 2022;119:e2113535119.
    PubMed     Abstract available


  3. GUPTA A, Smith P, Bournazos S, Ravetch JV, et al
    A novel mouse strain optimized for chronic human antibody administration.
    Proc Natl Acad Sci U S A. 2022;119:e2123002119.
    PubMed     Abstract available


    February 2022
  4. AURORA AB, Khivansara V, Leach A, Gill JG, et al
    Loss of glucose 6-phosphate dehydrogenase function increases oxidative stress and glutaminolysis in metastasizing melanoma cells.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


    January 2022
  5. KIM G, Wu Q, Chu JL, Smith EJ, et al
    Ultrasound controlled mechanophore activation in hydrogels for cancer therapy.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


    October 2021
  6. GANGAEV A, Rozeman EA, Rohaan MW, Isaeva OI, et al
    Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    September 2021
  7. STOPFER LE, Gajadhar AS, Patel B, Gallien S, et al
    Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    June 2021
  8. ZHAO J, Jaffe A, Li H, Lindenbaum O, et al
    Detection of differentially abundant cell subpopulations in scRNA-seq data.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    May 2021
  9. YIN Q, Yu W, Grzeskowiak CL, Li J, et al
    Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    April 2021
  10. YIN W, Li Y, Song Y, Zhang J, et al
    CCRL2 promotes antitumor T-cell immunity via amplifying TLR4-mediated immunostimulatory macrophage activation.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  11. FALAHAT R, Berglund A, Putney RM, Perez-Villarroel P, et al
    Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    March 2021
  12. TENGESDAL IW, Menon DR, Osborne DG, Neff CP, et al
    Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    February 2021
  13. ZHANG H, You X, Wang X, Cui L, et al
    Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    December 2020
  14. PATUTINA OA, Gaponova Miroshnichenko SK, Sen'kova AV, Savin IA, et al
    Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency.
    Proc Natl Acad Sci U S A. 2020;117:32370-32379.
    PubMed     Abstract available


  15. EISINGER S, Sarhan D, Boura VF, Ibarlucea-Benitez I, et al
    Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
    Proc Natl Acad Sci U S A. 2020;117:32005-32016.
    PubMed     Abstract available


    November 2020
  16. LU Y, Sandoval A, Voss S, Lai Z, et al
    Oncogenic allelic interaction in Xiphophorus highlights hybrid incompatibility.
    Proc Natl Acad Sci U S A. 2020;117:29786-29794.
    PubMed     Abstract available


    August 2020
  17. DEAN DN, Lee JC
    Defining an amyloid link Between Parkinson's disease and melanoma.
    Proc Natl Acad Sci U S A. 2020 Aug 31. pii: 2009702117.
    PubMed     Abstract available


  18. LI N, Kang Y, Wang L, Huff S, et al
    ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment.
    Proc Natl Acad Sci U S A. 2020;117:20159-20170.
    PubMed     Abstract available


    July 2020
  19. TAN J, Liu R, Zhu G, Umbricht CB, et al
    TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel.
    Proc Natl Acad Sci U S A. 2020;117:15846-15851.
    PubMed     Abstract available


    June 2020
  20. LEX K, Maia Gil M, Lopes-Bastos B, Figueira M, et al
    Telomere shortening produces an inflammatory environment that increases tumor incidence in zebrafish.
    Proc Natl Acad Sci U S A. 2020;117:15066-15074.
    PubMed     Abstract available


    May 2020
  21. PYO A, Kim DY, Kim H, Lim D, et al
    Ultrasensitive detection of malignant melanoma using PET molecular imaging probes.
    Proc Natl Acad Sci U S A. 2020 May 21. pii: 1922313117.
    PubMed     Abstract available


    April 2020

  22. Correction for AbuHammad et al., Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    Proc Natl Acad Sci U S A. 2020 Apr 20. pii: 2005945117.
    PubMed    


    March 2020
  23. NICOLET BP, Guislain A, van Alphen FPJ, Gomez-Eerland R, et al
    CD29 identifies IFN-gamma-producing human CD8(+) T cells with an increased cytotoxic potential.
    Proc Natl Acad Sci U S A. 2020;117:6686-6696.
    PubMed     Abstract available


  24. SHARMA S, Zhang T, Michowski W, Rebecca VW, et al
    Targeting the cyclin-dependent kinase 5 in metastatic melanoma.
    Proc Natl Acad Sci U S A. 2020 Mar 19. pii: 1912617117.
    PubMed     Abstract available


  25. HERMANS D, Gautam S, Garcia-Canaveras JC, Gromer D, et al
    Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8(+) T cell stemness and antitumor immunity.
    Proc Natl Acad Sci U S A. 2020;117:6047-6055.
    PubMed     Abstract available


    February 2020
  26. TZENG SY, Patel KK, Wilson DR, Meyer RA, et al
    In situ genetic engineering of tumors for long-lasting and systemic immunotherapy.
    Proc Natl Acad Sci U S A. 2020;117:4043-4052.
    PubMed     Abstract available


  27. MULLOKANDOV G, Vijayakumar G, Leon P, Henry C, et al
    High-complexity extracellular barcoding using a viral hemagglutinin.
    Proc Natl Acad Sci U S A. 2020;117:2767-2769.
    PubMed     Abstract available


    December 2019
  28. LEE CJ, An HJ, Kim SM, Yoo SM, et al
    FBXW7-mediated stability regulation of signal transducer and activator of transcription 2 in melanoma formation.
    Proc Natl Acad Sci U S A. 2019 Dec 16. pii: 1909879116.
    PubMed     Abstract available


    November 2019
  29. PREMI S, Han L, Mehta S, Knight J, et al
    Genomic sites hypersensitive to ultraviolet radiation.
    Proc Natl Acad Sci U S A. 2019 Nov 13. pii: 1907860116.
    PubMed     Abstract available


  30. LINETTE GP, Becker-Hapak M, Skidmore ZL, Baroja ML, et al
    Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Proc Natl Acad Sci U S A. 2019 Nov 4. pii: 1906026116.
    PubMed     Abstract available


    August 2019
  31. WANG X, Sun R, Hao X, Lian ZX, et al
    IL-17 constrains natural killer cell activity by restraining IL-15-driven cell maturation via SOCS3.
    Proc Natl Acad Sci U S A. 2019;116:17409-17418.
    PubMed     Abstract available


  32. ZHANG Y, Fang C, Wang RE, Wang Y, et al
    A tumor-targeted immune checkpoint blocker.
    Proc Natl Acad Sci U S A. 2019;116:15889-15894.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: